Sorafenib for the treatment of multiple myeloma.

about

PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells

P2860

Q38722800-0F9D49D3-7A6E-4532-A4A1-B937D30480E7

P2860

Sorafenib for the treatment of multiple myeloma.

Item

http://www.wikidata.org/entity/Q38783055

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Sorafenib for the treatment of multiple myeloma.

@en

type

Item

label

Sorafenib for the treatment of multiple myeloma.

@en

prefLabel

Sorafenib for the treatment of multiple myeloma.

@en

P1476

Sorafenib for the treatment of multiple myeloma

@en

P2093

Ernesto Vigna

http://www.w3.org/2001/XMLSchema#string

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Lucio Morabito

http://www.w3.org/2001/XMLSchema#string

Massimo Gentile

http://www.w3.org/2001/XMLSchema#string

P2860

Initial genome sequencing and analysis of multiple myeloma

Clinical and biological significance of RAS mutations in multiple myeloma.

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

P304

743-749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2016.1169272

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anna Grazia Recchia

Massimo Martino

P577

2016-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26998658

http://www.w3.org/2001/XMLSchema#string

Sorafenib for the treatment of multiple myeloma.

about

P2860

P2860

Sorafenib for the treatment of multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698